EGFR was used as a target for the treatment of gliomas in the included trial; while Wygoda et al. [16] concluded that EGFR-targeted RIT was not effective in high-grade gliomas, another phase II trial showed encouraging results in glioblastoma multiforme [44]. Here, EGFR is linked to central nervous system cancer.